ReviewJournal of translational medicine2026
Exosome-mediated muscle-bone crosstalk: mechanisms and therapeutic potential.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMuscle and bone maintain homeostasis through biomechanical and molecular crosstalk. Disruption of this interaction leads to osteosarcopenia, a condition marked by concurrent muscle and bone loss. Exosomes carry proteins and nucleic acids between tissues and are now recognized as key mediators of intercellular communication. Clarifying the role of exosomes in muscle-bone crosstalk is essential for identifying new biomarkers and therapeutic targets for musculoskeletal diseases. MAIN BODY: This review first summarizes the biogenesis and molecular composition of exosomes. It then examines the regulatory effects of skeletal muscle-derived exosomes on bone metabolism, focusing on how myogenic miRNAs and proteins influence osteoblast and osteoclast activity. The review also addresses the reverse pathway, describing how bone-derived exosomes, particularly those from BMSCs, affect myogenesis and muscle atrophy. We further assess their translational potential as circulating biomarkers, therapeutic delivery vehicles, and engineered platforms, while considering current limitations in isolation and characterization, biodistribution, manufacturing, safety, and regulatory oversight.
conclusionExosomes are critical mediators of muscle-bone crosstalk, with their cargo reflecting the physiological state of source cells. While exosome-based tools show promise for the diagnosis and treatment of conditions like osteosarcopenia, challenges remain in standardizing preparation methods and achieving tissue-specific delivery. Future work integrating multi-omics and artificial intelligence will be necessary to translate these findings into clinical applications for musculoskeletal health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.